Summary
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
History
In the mid-1980s, hematologist Laurence Corash developed a novel method of inactivating HIV particles contained in donated blood plasma using ultraviolet lights. He continued building prototypes with help from colleagues at the UC-San Francisco School of Medicine, and together with chemist John E. Hearst founded the company as Cerus Technologies Inc. on September 19, 1991, later to be renamed as Cerus Corporation in its initial 1996 SEC filing.
Mission
The mission of Cerus Corporation is focused on developing, commercializing and promoting innovative technologies to enhance blood safety and availability by enabling safer and more effective transfusion practices for healthcare professionals and patients.
Vision
Cerus Corporation's vision is to become the leading provider of biological safety products and processes throughout the global healthcare community.
Key Team
Mr. Vivek K. Jayaraman (Chief Operating Officer)
Dr. Richard J. Benjamin (Chief Medical Officer)
Ms. Lori L. Roll (VP of Admin. & Corp. Sec.)
Mr. Matthew M. Notarianni (Sr. Director of Investor Relations)
Ms. Chrystal N. Menard (Chief Legal Officer & Gen. Counsel)
Lainie Corten (VP of Global Marketing)
Ms. Carol M. Moore (Sr. VP of Regulatory Affairs, Quality & Clinical)
Recognition and Awards
Cerus Corporation has received numerous awards and honors, including the 2017 American Society of Hematology Association Volunteer Excellence Award, the 2016 Singapore Health and Biomedical Congress Innovation Award, and the American Society of Clinical Pathology's 2015 Outstanding Pathology Test Award.
References
United States 